These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 27439505)

  • 21. Few Drugs Display Flip-Flop Pharmacokinetics and These Are Primarily Associated with Classes 3 and 4 of the BDDCS.
    Garrison KL; Sahin S; Benet LZ
    J Pharm Sci; 2015 Sep; 104(9):3229-35. PubMed ID: 26010239
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neural Network Models for Predicting Solubility and Metabolism Class of Drugs in the Biopharmaceutics Drug Disposition Classification System (BDDCS).
    Ashrafi A; Teimouri K; Aghazadeh F; Shayanfar A
    Eur J Drug Metab Pharmacokinet; 2024 Jan; 49(1):1-6. PubMed ID: 37864650
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative Oral Drug Classification Systems: Acetazolamide, Azithromycin, Clopidogrel, and Efavirenz Case Studies.
    Mora MJ; Onnainty R; Granero GE
    Mol Pharm; 2018 Aug; 15(8):3187-3196. PubMed ID: 29927606
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A provisional biopharmaceutical classification of the top 200 oral drug products in the United States, Great Britain, Spain, and Japan.
    Takagi T; Ramachandran C; Bermejo M; Yamashita S; Yu LX; Amidon GL
    Mol Pharm; 2006; 3(6):631-43. PubMed ID: 17140251
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Analysis of the interplay of physiological response to food intake and drug properties in food-drug interactions.
    Sharma S; Kogan C; Varma MVS; Prasad B
    Drug Metab Pharmacokinet; 2023 Dec; 53():100518. PubMed ID: 37856928
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Distinguishing between the permeability relationships with absorption and metabolism to improve BCS and BDDCS predictions in early drug discovery.
    Larregieu CA; Benet LZ
    Mol Pharm; 2014 Apr; 11(4):1335-44. PubMed ID: 24628254
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Improving the prediction of the brain disposition for orally administered drugs using BDDCS.
    Broccatelli F; Larregieu CA; Cruciani G; Oprea TI; Benet LZ
    Adv Drug Deliv Rev; 2012 Jan; 64(1):95-109. PubMed ID: 22261306
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The developability classification system: application of biopharmaceutics concepts to formulation development.
    Butler JM; Dressman JB
    J Pharm Sci; 2010 Dec; 99(12):4940-54. PubMed ID: 20821390
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intestinal drug transporters: an overview.
    Estudante M; Morais JG; Soveral G; Benet LZ
    Adv Drug Deliv Rev; 2013 Oct; 65(10):1340-56. PubMed ID: 23041352
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The use of drug metabolism for prediction of intestinal permeability (dagger).
    Chen ML; Yu L
    Mol Pharm; 2009; 6(1):74-81. PubMed ID: 19132929
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel high/low solubility classification methods for new molecular entities.
    Dave RA; Morris ME
    Int J Pharm; 2016 Sep; 511(1):111-126. PubMed ID: 27349790
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predicting Interactions between Rifampin and Antihypertensive Drugs Using the Biopharmaceutics Drug Disposition Classification System.
    Liu W; Yan T; Chen K; Yang L; Benet LZ; Zhai S
    Pharmacotherapy; 2020 Apr; 40(4):274-290. PubMed ID: 32100890
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Predicting drug disposition, absorption/elimination/transporter interplay and the role of food on drug absorption.
    Custodio JM; Wu CY; Benet LZ
    Adv Drug Deliv Rev; 2008 Mar; 60(6):717-33. PubMed ID: 18199522
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The utility of rat jejunal permeability for biopharmaceutics classification system.
    Zakeri-Milani P; Valizadeh H; Tajerzadeh H; Islambulchilar Z
    Drug Dev Ind Pharm; 2009 Dec; 35(12):1496-502. PubMed ID: 19929209
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Computational models to assign biopharmaceutics drug disposition classification from molecular structure.
    Khandelwal A; Bahadduri PM; Chang C; Polli JE; Swaan PW; Ekins S
    Pharm Res; 2007 Dec; 24(12):2249-62. PubMed ID: 17846869
    [TBL] [Abstract][Full Text] [Related]  

  • 36. BDDCS, the Rule of 5 and drugability.
    Benet LZ; Hosey CM; Ursu O; Oprea TI
    Adv Drug Deliv Rev; 2016 Jun; 101():89-98. PubMed ID: 27182629
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Projecting ADME Behavior and Drug-Drug Interactions in Early Discovery and Development: Application of the Extended Clearance Classification System.
    El-Kattan AF; Varma MV; Steyn SJ; Scott DO; Maurer TS; Bergman A
    Pharm Res; 2016 Dec; 33(12):3021-3030. PubMed ID: 27620173
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hepatic Clearance Predictions from In Vitro-In Vivo Extrapolation and the Biopharmaceutics Drug Disposition Classification System.
    Bowman CM; Benet LZ
    Drug Metab Dispos; 2016 Nov; 44(11):1731-1735. PubMed ID: 27519549
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In Situ Intestinal Perfusion in Rodents: Future Perspectives for Application on Absorption Studies and Classification of Drugs.
    Dezani TM; Dezani AB; de Silva MMC; Dos Reis Serra CH
    Mini Rev Med Chem; 2017; 17(9):746-757. PubMed ID: 27659249
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Generative topographic mapping-based classification models and their applicability domain: application to the biopharmaceutics Drug Disposition Classification System (BDDCS).
    Gaspar HA; Marcou G; Horvath D; Arault A; Lozano S; Vayer P; Varnek A
    J Chem Inf Model; 2013 Dec; 53(12):3318-25. PubMed ID: 24320683
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.